Brand Intelligence Graph
Company Overview
About Tune Therapeutics
Tune Therapeutics is an epigenome editing company that silences disease-causing genes without making permanent DNA cuts — a potentially safer approach than traditional gene editing for chronic diseases. The company raised $175 million in Series B financing led by Hevolution Foundation (the world's largest longevity-focused philanthropic fund), NEA, and Regeneron Ventures, and has dosed its first patient in Phase 1/2 clinical trials for Tune-401, targeting chronic hepatitis B.
Business Model & Competitive Advantage
Chronic hepatitis B (CHB) affects 296 million people globally and is not curable with existing antivirals because HBV DNA integrates into the human genome and forms covalently closed circular DNA (cccDNA) that persists indefinitely. Tune-401 simultaneously silences both integrated HBV DNA and episomal cccDNA using epigenetic writers that methylate viral promoters without cutting DNA — the first approach capable of targeting both reservoirs simultaneously.
Competitive Landscape 2025–2026
Tune's TEMPO platform can theoretically be applied to any disease where gene silencing (rather than permanent knockout) is the therapeutic objective — including oncology, inflammatory disease, and neurological conditions. The Regeneron Ventures participation provides strategic access to Regeneron's protein engineering capabilities and potential co-development agreements for combination therapies that pair TEMPO silencing with Regeneron's monoclonal antibodies.
Key Differentiators
Emerging Innovator
Tune Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Tune Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tune Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tune Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tune Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →